Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-Interventional Study to Investigate the Durable Effectiveness of Risankizumab Using Digital and Remote Evaluation Tools in Moderate to Severe Psoriasis Patients - prIMMa Study

NCT04780516 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04780516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04780516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-Interventional Study to Investigate the Durable Effectiveness of Risankizumab Using Digital and Remote Evaluation Tools in Moderate to Severe Psoriasis Patients - prIMMa Study
Lead sponsor
AbbVie
Phase
Observational
Overall status
Active, not recruiting
Start date
April 26, 2021
Completion date
December 31, 2026
Enrollment
141 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis